Join
Live feed
·
PRReleasevia Quantisnow
Gritstone bio Inc. logo

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer

ByQuantisnow·Wall Street's wire, on your screen.
GRTS· Gritstone bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GRTS (Gritstone bio Inc.) and more on Quantisnow.